Electromed Inc

Research Electromed Inc (ELMD) on Bullrun: valuation model: 2.2% overvalued, market cap USD 325.74M, P/E 33.8. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

Bullrun's latest valuation model marks Electromed Inc as 2.2% overvalued; latest market cap is USD 325.74M; P/E is 33.8.

Peer valuation comparison

Latest P/E is 33.8x versus a Healthcare sector median of 24.46x (38.2% above).

Latest P/E is 33.8x versus a United States median of 24.87x (35.9% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 64.00MUSD 7.54MUSD 11.13M78.1%0.85USD 15.29Mn/aUSD 43.21M
FY2024USD 54.72MUSD 5.15MUSD 8.78M76.3%0.58USD 16.08Mn/aUSD 44.55M
FY2023USD 48.07MUSD 3.17M-USD 333.00K76.0%0.36USD 7.37Mn/aUSD 37.67M
FY2022USD 41.66MUSD 2.31M-USD 2.11M75.5%0.26USD 8.15Mn/aUSD 34.17M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 325.74M33.8n/an/a
20252025-12-31USD 241.10M28.3n/an/a
20242024-12-31USD 252.85M38.9n/an/a
20232023-12-29USD 93.63M29.5n/an/a
20222022-12-30USD 89.01M47.7n/an/a
20212021-12-31USD 110.93M59.1n/an/a

About Electromed Inc

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.

Related stock research

Other Healthcare stocks

Frequently asked questions

Is Electromed Inc overvalued or undervalued?

Bullrun's valuation model currently marks Electromed Inc as 2.2% overvalued.

What is Electromed Inc's market cap?

Electromed Inc's market capitalization is USD 325.74M.

What is Electromed Inc's P/E ratio?

Electromed Inc's price-to-earnings (P/E) ratio is 33.8.

What does Electromed Inc do?

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally.